Fluorophore−Quencher Based Activatable Targeted Optical Probes for Detecting in Vivo Cancer Metastases

Publisher Website
Google Scholar
Abstract
In vivo molecularly targeted fluorescence imaging of tumors has been proposed as a strategy for improving cancer detection and management. Activatable fluorophores, which increased their fluorescence by 10-fold after binding tumor cells, result in much higher target to background ratios than conventional fluorophores. We developed an in vivo targeted activatable optical imaging probe based on a fluorophore−quencher pair, bound to a targeting moiety. With this system, fluorescence is quenched by the fluorophore−quencher interaction outside cancer cells, but is activated within the target cells by dissociation of the fluorophore−quencher pair. We selected the TAMRA (fluorophore)−QSY7 (quencher) pair and conjugated it to either avidin (targeting the d-galactose receptor) or trastuzumab (a monoclonal antibody against the human epithelial growth factor receptor type2 (HER2/neu)) and evaluated their performance in mouse models of cancer. Two probes, TAMRA−QSY7 conjugated avidin (Av-TM-Q7) and trastuzumab (Traz-TM-Q7) were synthesized. Both demonstrated better than similar self-quenching probes. In vitro fluorescence microscopic studies of SHIN3 and NIH/3T3/HER2+ cells demonstrated that Av-TM-Q7 and Traz-TM-Q7 produced high intracellular fluorescent signal. In vivo imaging with Av-TM-Q7 and Traz-TM-Q7 in mice enabled the detection of small tumors. This molecular imaging probe, based on a fluorophore−quencher pair conjugated to a targeting ligand, successfully detected tumors in vivo due to its high activation ratio and low background signal. Thus, these activatable probes, based on the fluorophore−quencher system, hold promise clinically for “see and treat” strategies of cancer management.